[328 Pages Report] The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market was valued at US$ 3.8 Bn in 2021 and is expected to reach US$ 5.5 Bn by 2030, finds Future Market Insights (FMI) in a recent market survey.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 3.9 Billion |
| Market Value 2030 | USD 5.5 Billion |
| CAGR 2022 to 2030 | 4.3% |
| Key Players | The key players are Pfizer, Inc., Allergan Plc., Johnsons & Johnson, Colgate-Palmolive Company, The Procter & Gamble, Merck & Co., Inc., Baxter Healthcare Corporation, Fresenius Kabi LLC, Sandoz Inc., Teva Pharmaceutical Industries ltd., Mylan N. V., Dr.Reddy's Laboratories Inc., Cumberland Pharmaceuticals Inc., Durata Therapeutics Inc., Melinta Therapeutics, Inc., Debiopharm International S.A., Cardinal Health, Amazon Inc., Herbal Intervention, LLC, 3M ESPE Dental Products, Patterson Dental Supply Inc., The Kroger Company, Crown Laboratories, Inc., Atlantic Biologicals Corp., Bio-Germ Protection LLC and Apollo Health and Beauty Care |
| Share of Top 5 Countries | 65.9% |
The methicillin-resistant staphylococcus aureus (MRSA) treatment market is anticipated to witness robust growth due to the growing incidence rate of MRSA infections, increasing number of pipeline products, and growing product approval & launches for the MRSA infection treatment.
One of the significant type of MRSA infection is surgical infections. This risk of infections is associated with several surgical conditions which demand surgical procedures. Rising number of surgical conditions from chronic diseases such as diabetes, chronic respiratory and renal diseases are expected to increase the demand of post-operative MRSA anti-infective therapies.
Methicillin-resistant staphylococcus aureus (MRSA) treatment market holds nearly 18.1% market value share of the US$ 21 Bn skin disease treatment market in 2021. In addition, leading industry players are focusing on development and launch of next generation antibiotics to treat MRSA infections. This accelerated availability of antibiotics in the market is expected to boost the MRSA treatment market.
Driven by this, sales of methicillin-resistant staphylococcus aureus (MRSA) treatment are expected to rise at a 4.3% CAGR through 2030.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 4.25% |
| H1, 2022 Projected | 4.34% |
| H1, 2022 Outlook | 4.24% |
| BPS Change - H1, 2022 (O) – H1, 2022 (P) | (-) 10 ↓ |
| BPS Change – H1, 2022 (O) – H1, 2021 | (-) 1 ↓ |
FMI presents a comparative analysis about the market growth rates and development prospects in the global methicillin resistant Staphylococcus aureus (MRSA) treatment market. In response to the impact of macro and industrial factors, the market is influenced by an increase in patient base and economic disparities in regional medical setups. Source control and the initiation of active antimicrobial therapy are two major advancements in this sector.
The market for methicillin-resistant Staphylococcus aureus (MRSA) therapy is expected to fall by just 01 Basis Point Share (BPS) in H1-2022, according to FMI. The disruption created by the COVID-19 pandemic, as well as the lack of clear protocols for MRSA treatment in numerous countries, are key factors in the decline of BPS. Moreover, a decline of 10 BPS will be observed in the market within the periods of H1-2022 outlook over H1-2022 projected.
On the other hand, there are certain advantages for the industry, such as combination therapy with Vancomycin and Daptomycin. Physicians employ heterogeneous practice patterns with vancomycin or daptomycin monotherapy for MRSA, with combination antibiotic therapy reserved for patients at higher risk of treatment failure.
Sales of methicillin-resistant staphylococcus aureus (MRSA) treatment grew at a CAGR of 4.1% between 2015 and 2021.
The primary factors contributing to the development of the methicillin-resistant staphylococcus aureus (MRSA) treatment market are increase in the worldwide occurrence of MRSA infections, a rise in public and private funding for R&D of new anti-MRSA drugs and their enhanced screening.
For instance, as per the CDC, around 2% of the overall population carries MRSA. Moreover, the growing practice of prescribing inappropriate and unnecessary antibiotics leading to the increase in MRSA infections is expected to boost the growth of the global market.
In addition, companies are focusing on product releases and research for the detection of MRSA, which is boosting the global MRSA treatment market.
For instance, in February 2019, Paratek Pharmaceuticals, Inc. launched NUZYRA (omadacycline) in the U.S. market.
Considering this, FMI expects the global methicillin-resistant staphylococcus aureus (MRSA) treatment market to grow at a CAGR of 4.3% through 2030.
Principal Consultant
Poor access to MRSA treatment and misdiagnoses of MRSA infections are the primary factors limiting the growth of the MSRA treatment market.
S. aureus and MRSA produce considerable economic challenges for healthcare professionals owing to the effect they have on quality of care, patient safety, and overall healthcare expenses. High cost related with MRSA infections treatment is anticipated to hinder the treatment adoption rate specifically in emerging regions.
In addition, incorrect diagnoses of MRSA may result into inappropriate delivery and management of patient care, which, in turn, results into severe primary and secondary complications, including death. All such factors may hinder the market growth in the near future.
The U.S. is estimated to account for around 93.2% of the North America methicillin-resistant staphylococcus aureus (MRSA) treatment market in 2022.
U.S. is anticipated to lead the global MRSA treatment market over the forecast period. This market share is majorly owing to the funding by U.S. based companies in the research and development of assessment tools for MRSA infection. In addition, the increase in government support for treatment of MRSA lung infection in patients with cystic fibrosis has boosted the market.
For instance, Cystic Fibrosis Foundation, in 2018, at North American Cystic Fibrosis Conference declared that it will spend a minimum of USD 100 million for the next five years to support enhanced diagnosis, detection, prevention, and treatment of infections associated to cystic fibrosis.
U.K. is estimated to account for 14.7% of the Europe methicillin-resistant staphylococcus aureus (MRSA) treatment market in 2022.
U.K. is the one of the prominent country in the European market owing to research grants by the private & public companies in the European countries to boost the research and development of anti-MRSA antibiotics.
In addition, the government of the UK is undertaking serious steps to avoid the incidence of SSI (surgical site infections) in the nation. Thus, the increasing efforts and preventive measures undertaken by the government for surgical site infections control are leading to the growth of the market in U.K.
The methicillin-resistant staphylococcus aureus (MRSA) treatment market in China is estimated to be worth US$ 156.6 Mn in 2022 in the global market.
China is expected to observe considerable growth during the forecast period owing to a huge patient pool and growing number of expansion strategies by key players to grow their presence in the country.
For instance, in 2017, Basilea Pharmaceutica Ltd. entered into a licensed agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for expansion of Basilea's antibiotic Zevtera, broad spectrum anti-bacterial, which can address MRSA in China, Hong Kong, and Macao
Demand for methicillin-resistant staphylococcus aureus (MRSA) treatment in India is expected to rise at around 5.4% CAGR over the forecast period.
India is expected to witness considerable growth owing to larger patient population and the uncontrolled utilization of antibiotics in India. Resistance to antibiotics is continuously growing due to incomplete prescribed course of antibiotics that allows some bacteria to persist, grow a resistance to the antibiotic.
Moreover, misuse of antibiotics in non-regulated and developing nations is also anticipated to drive the cases of MRSA infections in the coming years. This is leading to increasing demand for the MRSA infection treatment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By drug class, glycopeptides is anticipated to hold the maximum share of 61.2% in 2022, expanding at rate of nearly 4.1% during the forecast period, due to growing focus of market players on manufacturing of advanced drugs in this class. Vancomycin and teicoplanin are some of the present glycopeptide drugs in the market.
Moreover, in 2017, Cardiome Pharma Corp. launched Xydalba in Sweden, Finland, and the Republic of Ireland. Xydalba is approved by the European Medicines Agency (EMA) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults.
By indication, skin and soft tissue infections (SSTIs) will lead the market and is projected to account for 40.9% of the total market revenue share in 2022.
The growing incidence of MRSA (methicillin-resistant staphylococcus aureus) infections has led to the need for novel therapies to fight the serious skin and soft tissue infections. Moreover, new product launches will drive the growth of the skin and soft tissue infections (SSTIs) segment over the forecast period.
In terms of route of administration, intravenous segment in projected to account for 57.2% of the total market share in 2022.
The intravenous route of administration is the most preferred route as it is the first line of therapy and the fastest route of drug delivery. This delivers the drug rapidly and gives the patient rapid relieve from the disease. This enhances the drug action and gives the patient first line of treatment.
By types of MRSA, healthcare acquired MRSA will lead the market and is projected to account for 51.2% of the total market revenue share in 2022.
Hospital-acquired MRSA hospitalizations are those with a secondary or principal MRSA detection that is not present on admission; this indicates that the MRSA condition occurred during the hospitalization. The hospital acquired MSRA cases is increasing due to the rising number of surgical procedures and unhygienic conditions.
By distribution channel, hospital pharmacies segment is anticipated to hold the maximum share of 62.6% in 2022, expanding at rapid rate of 3.9% CAGR during the forecast period.
The number of hospitals are growing, particularly in the developed nations, which is anticipated to surge the demand for methicillin-resistant staphylococcus aureus (MRSA) treatment in hospitals. Moreover, presence of well-developed infrastructure and availability of advanced equipment supports the development of the segment.
Also, the increasing patient admission in hospitals is increasing the use of these drugs in hospitals, thus driving the sales in hospital pharmacies.
Companies operating in the Methicillin-Resistant Staphylococcus Aureus (MRSA) treatment market are moderately competitive by nature, with a presence of several players. These players are involved in a number of strategic alliances. The product launch and acquisition accelerates the manufacturer’s strategy to capitalize on the market share and capture the significant share of market. Some of the recent instances include:
| Attribute | Details |
|---|---|
| Forecast Period | 2015 to 2021 |
| Historical Data Available for | 2022 to 2030 |
| Market Analysis | USD Million for Value |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, BENELUX, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa |
| Key Segments Covered | Drug Class, Indication, Route of Administration, Types of MSRA, Distribution Channel and Region |
| Key Companies Profiled | Pfizer, Inc.; Allergan Plc.; Johnsons & Johnson; Colgate-Palmolive Company; The Procter & Gamble; Merck & Co., Inc.; Baxter Healthcare Corporation; Fresenius Kabi LLC; Sandoz Inc.; Teva Pharmaceutical Industries ltd.; Mylan N. V.; Dr.Reddy's Laboratories Inc.; Cumberland Pharmaceuticals Inc.; Durata Therapeutics Inc.; Melinta Therapeutics, Inc.; Debiopharm International S.A.; Cardinal Health; Amazon Inc.; Herbal Intervention, LLC; 3M ESPE Dental Products; Patterson Dental Supply Inc.; The Kroger Company; Crown Laboratories, Inc.; Atlantic Biologicals Corp.; Bio-Germ Protection LLC; Apollo Health and Beauty Care |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global methicillin-resistant staphylococcus aureus (MRSA) treatment market is worth US$ 3.8 Bn in 2021 and is set to expand 1.4X over the forecast years.
The sales of methicillin-resistant staphylococcus aureus (MRSA) treatment in the market have grown at a CAGR of nearly 4.1% between 2015 and 2021.
The methicillin-resistant staphylococcus aureus (MRSA) treatment market is expected to reach US$ 5.5 Bn by the end of 2030 with sales revenue expected to register CAGR of 4.3% over the forecast period.
North America currently holds the largest market share in the methicillin-resistant staphylococcus aureus (MRSA) treatment with an estimation of nearly 48.5% in 2022 of the global market share. U.S. continues to be the leading contributor with a market value over US$ 1.7 Bn in 2022.
Demand of methicillin-resistant staphylococcus aureus (MRSA) treatment market is expected to register growth in Europe at rate of 4.4% CAGR during the forecast period.
The methicillin-resistant staphylococcus aureus (MRSA) treatment in China is likely to observe growth with an impressive CAGR of 5.1% during the forecast period. The key factors fueling the development of the market include huge patient pool and growing number of expansion strategies by key players to grow their presence in the country.
Development of alternative oral & topical dosage forms, extension of antibiotic class to newer therapeutics, rise of specialized companies in antibiotics developments and commercialization and national healthcare authority’s active engagement to combat MRSA are key trends driving sales of methicillin-resistant staphylococcus aureus (MRSA) treatment market across the globe.
Japan’s methicillin-resistant staphylococcus aureus (MRSA) treatment market is offering lucrative growth opportunities and is expected to exhibit healthy growth of 5.6% CAGR during the forecast period. South Korea market expected to exhibit healthy growth of 7.0% CAGR during the forecast period.
U.S., Germany, France, U.K. and Italy are the top 5 countries driving the demand for methicillin-resistant staphylococcus aureus (MRSA) treatment market.
Leading companies of methicillin-resistant staphylococcus aureus (MRSA) treatment are Pfizer, Inc., Allergan Plc., Johnsons & Johnson, Colgate-Palmolive Company, The Procter & Gamble, Merck & Co., Inc., Baxter Healthcare Corporation, Fresenius Kabi LLC, Sandoz Inc., Teva Pharmaceutical Industries ltd., Mylan N. V., Dr.Reddy's Laboratories Inc., Cumberland Pharmaceuticals Inc., Durata Therapeutics Inc., Melinta Therapeutics, Inc., Debiopharm International S.A., Cardinal Health, Amazon Inc., Herb
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Market Background
4.1. COVID19 Crisis Analysis
4.1.1. Current COVID19 Statistics and Probable Future Impact
4.1.2. Current GDP Projection and Probable Impact
4.1.3. Current Economic Projection as compared to 2008 Economic analysis
4.1.4. COVID19 and Impact Analysis
4.1.4.1. Revenue By Drug Class
4.1.4.2. Revenue By Route of Administration
4.1.4.3. Revenue By Country
4.1.5. 2020 Market Scenario
4.1.6. Quarter by Quarter Forecast
4.1.7. Projected recovery Quarter
4.1.8. Recovery Scenario – Short term, Midterm and Long Term Impact
4.2. Macro-Economic Factors
4.2.1. Global GDP Growth Outlook
4.2.2. Global Healthcare Outlook
4.3. Forecast Factors - Relevance & Impact
4.3.1. Historical Growth of Top Players
4.3.2. New Product Approval and Launch
4.3.3. Adoption of MRSA Treatment
4.3.4. Cost of MRSA Treatment
4.3.5. Increasing Epidemic of MRSA Infections
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
5. Market Context
5.1. Product USPs/ Features
5.2. Epidemiological Forecast for MRSA (2014–2024)
5.2.1. Hospitalized Incident Cases of MRSA
5.2.2. Sex-Specific Hospitalized Incident Cases of MRSA
5.2.3. Age-Specific Hospitalized Incidence of MRSA
5.2.4. Age-Standardized Hospitalized Incidence Rate of MRSA
5.3. Pipeline Assessment
5.3.1. Pipeline Overview
5.3.2. Pipeline Breakdown by Region/Country
5.3.3. Pipeline Breakdown by Molecule Type and Target
5.3.4. Drug Review Designations
5.3.5. Products in Clinical Development
5.4. New Product Approvals
5.5. Clinical Trial Assessment
5.5.1. Clinical Trials Overview
5.5.2. Top Sponsors of Clinical Trials in MRSA
5.5.3. Trial Breakdown by Region
5.5.4. Therapy Area Perspective
5.5.5. Enrolment Analytics
5.6. Product Adoption / Route of Administration Analysis
5.7. Regulatory Scenario
6. Global MRSA Treatment Market Value (US$ Mn) Analysis 2015-2021 and Forecast, 2022-2030
6.1. Historical Market Value (US$ Mn) Analysis, 2015-2021
6.2. Current and Future Market Value (US$ Mn) Projections, 2022-2030
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Opportunity Analysis, 2022-2030
7. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Drug Class
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015-2021
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022-2030
7.3.1. Glycopeptides
7.3.1.1. Vancomycin
7.3.2. Lipopeptides
7.3.2.1. Daptomycin
7.3.3. Oxazolidinones
7.3.3.1. Linezolid
7.3.4. Glycylcycline
7.3.4.1. Tigecycline
7.3.5. Streptogramins
7.3.5.1. Quinupristin
7.3.5.2. Dalfopristin
7.3.6. Lincomycin
7.3.6.1. Clindamycin
7.3.7. Tetracycline
7.3.7.1. Doxycycline
7.3.7.2. Minocycline
7.3.8. Lipoglycopeptides
7.3.8.1. Dalbavancin
7.3.8.12. Telavancin
7.3.8.3. Oritavancin
7.3.9. Antiseptics
7.3.9.1. Chlorhexidine
7.3.9.2. Cetylpyridinium Chloride
7.3.9.3. Hydrogen Peroxide
7.3.9.4. Phenols
7.3.10. Naturals/Herbals
7.3.11. Others
7.4. Market Attractiveness Analysis By Drug Class
8. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022-2030
8.3.1. Skin and Soft Tissue Infections (SSTIs)
8.3.2. Pneumonia
8.3.3. Bloodstream Infections
8.3.4. Surgical and Medical Infections
8.3.5. Others
8.4. Market Attractiveness Analysis By Indication
9. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2030
9.3.1. Intravenous
9.3.2. Oral
9.3.3. Topical
9.3.4. Nasal
9.3.5. Cutaneous
9.3.6. Intramuscular
9.4. Market Attractiveness Analysis By Route of Administration
10. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Types of MRSA
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Types of MRSA, 2022-2030
10.3.1. Healthcare Acquired MRSA
10.3.2. Community Acquired MRSA
10.3.3. Hospital Acquired MRSA
10.4. Market Attractiveness Analysis By Types of MRSA
11. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Distribution Channels
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channels, 2015-2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channels, 2022-2030
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Drug Stores
11.3.4. Online Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channels
12. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Region
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2030
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia Pacific
12.3.6. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Drug Class
13.3.3. By Indication
13.3.4. By Route of Administration
13.3.5. By Types of MRSA
13.3.6. By Distribution Channels
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. Latin America MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug Class
14.3.3. By Indication
14.3.4. By Route of Administration
14.3.5. By Types of MRSA
14.3.6. By Distribution Channels
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. Europe MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Drug Class
15.3.3. By Indication
15.3.4. By Route of Administration
15.3.5. By Types of MRSA
15.3.6. By Distribution Channels
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. South Asia and Oceania MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
16.3.1. By Country
16.3.1.1. India
16.3.1.2. ASEAN
16.3.1.3. Australia
16.3.1.4. New Zealand
16.3.2. By Drug Class
16.3.3. By Indication
16.3.4. By Route of Administration
16.3.5. By Types of MRSA
16.3.6. By Distribution Channels
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. East Asia MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Drug Class
17.3.3. By Indication
17.3.4. By Route of Administration
17.3.5. By Types of MRSA
17.3.6. By Distribution Channels
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. Oceania MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Drug Class
18.3.3. By Indication
18.3.4. By Route of Administration
18.3.5. By Types of MRSA
18.3.6. By Distribution Channels
18.4. Market Attractiveness Analysis
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
19. Middle East and Africa MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. South Africa
19.3.1.4. Rest of Middle East and Africa
19.3.2. By Drug Class
19.3.3. By Indication
19.3.4. By Route of Administration
19.3.5. By Types of MRSA
19.3.6. By Distribution Channels
19.4. Market Attractiveness Analysis
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
20. Emerging Countries MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030
20.1. Introduction
20.1.1. Market Value Proportion Analysis, By Key Countries
20.1.2. Global Vs. Country Growth Comparison
20.2. China MRSA Treatment Market Analysis
20.2.1. By Drug Class
20.2.2. By Indication
20.2.3. By Route of Administration
20.2.4. By Types of MRSA
20.2.5. By Distribution Channels
20.3. India MRSA Treatment Market Analysis
20.3.1. By Drug Class
20.3.2. By Indication
20.3.3. By Route of Administration
20.3.4. By Types of MRSA
20.3.5. By Distribution Channels
20.4. Brazil MRSA Treatment Market Analysis
20.4.1. By Drug Class
20.4.2. By Indication
20.4.3. By Route of Administration
20.4.4. By Types of MRSA
20.4.5. By Distribution Channels
21. Key Countries MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030
21.1. U.S. MRSA Treatment Market Analysis
21.1.1. By Drug Class
21.1.2. By Indication
21.1.3. By Route of Administration
21.1.4. By Types of MRSA
21.1.5. By Distribution Channels
21.2. Canada MRSA Treatment Market Analysis
21.2.1. By Drug Class
21.2.2. By Indication
21.2.3. By Route of Administration
21.2.4. By Types of MRSA
21.2.5. By Distribution Channels
21.3. Mexico MRSA Treatment Market Analysis
21.3.1. By Drug Class
21.3.2. By Indication
21.3.3. By Route of Administration
21.3.4. By Types of MRSA
21.3.5. By Distribution Channels
21.4. U.K. MRSA Treatment Market Analysis
21.4.1. By Drug Class
21.4.2. By Indication
21.4.3. By Route of Administration
21.4.4. By Types of MRSA
21.4.5. By Distribution Channels
21.5. Germany MRSA Treatment Market Analysis
21.5.1. By Drug Class
21.5.2. By Indication
21.5.3. By Route of Administration
21.5.4. By Types of MRSA
21.5.5. By Distribution Channels
21.6. France MRSA Treatment Market Analysis
21.6.1. By Drug Class
21.6.2. By Indication
21.6.3. By Route of Administration
21.6.4. By Types of MRSA
21.6.5. By Distribution Channels
21.7. Italy MRSA Treatment Market Analysis
21.7.1. By Drug Class
21.7.2. By Indication
21.7.3. By Route of Administration
21.7.4. By Types of MRSA
21.7.5. By Distribution Channels
21.8. Spain MRSA Treatment Market Analysis
21.8.1. By Drug Class
21.8.2. By Indication
21.8.3. By Route of Administration
21.8.4. By Types of MRSA
21.8.5. By Distribution Channels
21.9. BENELUX MRSA Treatment Market Analysis
21.9.1. By Drug Class
21.9.2. By Indication
21.9.3. By Route of Administration
21.9.4. By Types of MRSA
21.9.5. By Distribution Channels
21.10. Russia MRSA Treatment Market Analysis
21.10.1. By Drug Class
21.10.2. By Indication
21.10.3. By Route of Administration
21.10.4. By Types of MRSA
21.10.5. By Distribution Channels
21.11. Japan MRSA Treatment Market Analysis
21.11.1. By Drug Class
21.11.2. By Indication
21.11.3. By Route of Administration
21.11.4. By Types of MRSA
21.11.5. By Distribution Channels
21.12. South Korea MRSA Treatment Market Analysis
21.12.1. By Drug Class
21.12.2. By Indication
21.12.3. By Route of Administration
21.12.4. By Types of MRSA
21.12.5. By Distribution Channels
21.13. ASEAN MRSA Treatment Market Analysis
21.13.1. By Drug Class
21.13.2. By Indication
21.13.3. By Route of Administration
21.13.4. By Types of MRSA
21.13.5. By Distribution Channels
21.14. Australia MRSA Treatment Market Analysis
21.14.1. By Drug Class
21.14.2. By Indication
21.14.3. By Route of Administration
21.14.4. By Types of MRSA
21.14.5. By Distribution Channels
21.15. New Zealand MRSA Treatment Market Analysis
21.15.1. By Drug Class
21.15.2. By Indication
21.15.3. By Route of Administration
21.15.4. By Types of MRSA
21.15.5. By Distribution Channels
21.16. GCC Countries MRSA Treatment Market Analysis
21.16.1. By Drug Class
21.16.2. By Indication
21.16.3. By Route of Administration
21.16.4. By Types of MRSA
21.16.5. By Distribution Channels
21.17. Turkey MRSA Treatment Market Analysis
21.17.1. By Drug Class
21.17.2. By Indication
21.17.3. By Route of Administration
21.17.4. By Types of MRSA
21.17.5. By Distribution Channels
21.18. South Africa MRSA Treatment Market Analysis
21.18.1. By Drug Class
21.18.2. By Indication
21.18.3. By Route of Administration
21.18.4. By Types of MRSA
21.18.5. By Distribution Channels
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Market Presence Analysis
22.3.1. Regional Footprint by Players
22.3.2. Product Foot print by Players
22.3.3. Channel Foot Print by Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive (Tentative List)
23.3.1. Pfizer, Inc.
23.3.1.1. Overview
23.3.1.2. Product Portfolio
23.3.1.3. Profitability by Market Segments (Product/Channel/Region)
23.3.1.4. Sales Footprint
23.3.1.5. Strategy Overview
23.3.1.5.1. Marketing Strategy
23.3.1.5.2. Product Strategy
23.3.1.5.3. Channel Strategy
23.3.2. Allergan Plc.
23.3.2.1. Overview
23.3.2.2. Product Portfolio
23.3.2.3. Profitability by Market Segments (Product/Channel/Region)
23.3.2.4. Sales Footprint
23.3.2.5. Strategy Overview
23.3.2.5.1. Marketing Strategy
23.3.2.5.2. Product Strategy
23.3.2.5.3. Channel Strategy
23.3.3. Johnsons & Johnson
23.3.3.1. Overview
23.3.3.2. Product Portfolio
23.3.3.3. Profitability by Market Segments (Product/Channel/Region)
23.3.3.4. Sales Footprint
23.3.3.5. Strategy Overview
23.3.3.5.1. Marketing Strategy
23.3.3.5.2. Product Strategy
23.3.3.5.3. Channel Strategy
23.3.4. Colgate-Palmolive Company
23.3.4.1. Overview
23.3.4.2. Product Portfolio
23.3.4.3. Profitability by Market Segments (Product/Channel/Region)
23.3.4.4. Sales Footprint
23.3.4.5. Strategy Overview
23.3.4.5.1. Marketing Strategy
23.3.4.5.2. Product Strategy
23.3.4.5.3. Channel Strategy
23.3.5. The Procter & Gamble
23.3.5.1. Overview
23.3.5.2. Product Portfolio
23.3.5.3. Profitability by Market Segments (Product/Channel/Region)
23.3.5.4. Sales Footprint
23.3.5.5. Strategy Overview
23.3.5.5.1. Marketing Strategy
23.3.5.5.2. Product Strategy
23.3.5.5.3. Channel Strategy
23.3.6. Merck & Co., Inc.
23.3.6.1. Overview
23.3.6.2. Product Portfolio
23.3.6.3. Profitability by Market Segments (Product/Channel/Region)
23.3.6.4. Sales Footprint
23.3.6.5. Strategy Overview
23.3.6.5.1. Marketing Strategy
23.3.6.5.2. Product Strategy
23.3.6.5.3. Channel Strategy
23.3.7. Baxter Healthcare Corporation
23.3.7.1. Overview
23.3.7.2. Product Portfolio
23.3.7.3. Profitability by Market Segments (Product/Channel/Region)
23.3.7.4. Sales Footprint
23.3.7.5. Strategy Overview
23.3.7.5.1. Marketing Strategy
23.3.7.5.2. Product Strategy
23.3.7.5.3. Channel Strategy
23.3.8. Fresenius Kabi LLC
23.3.8.1. Overview
23.3.8.2. Product Portfolio
23.3.8.3. Profitability by Market Segments (Product/Channel/Region)
23.3.8.4. Sales Footprint
23.3.8.5. Strategy Overview
23.3.8.5.1. Marketing Strategy
23.3.8.5.2. Product Strategy
23.3.8.5.3. Channel Strategy
23.3.9. Sandoz Inc.
23.3.9.1. Overview
23.3.9.2. Product Portfolio
23.3.9.3. Profitability by Market Segments (Product/Channel/Region)
23.3.9.4. Sales Footprint
23.3.9.5. Strategy Overview
23.3.9.5.1. Marketing Strategy
23.3.9.5.2. Product Strategy
23.3.9.5.3. Channel Strategy
23.3.10. Teva Pharmaceutical Industries ltd.
23.3.10.1. Overview
23.3.10.2. Product Portfolio
23.3.10.3. Profitability by Market Segments (Product/Channel/Region)
23.3.10.4. Sales Footprint
23.3.10.5. Strategy Overview
23.3.10.5.1. Marketing Strategy
23.3.10.5.2. Product Strategy
23.3.10.5.3. Channel Strategy
23.3.11. Mylan N. V.
23.3.11.1. Overview
23.3.11.2. Product Portfolio
23.3.11.3. Profitability by Market Segments (Product/Channel/Region)
23.3.11.4. Sales Footprint
23.3.11.5. Strategy Overview
23.3.11.5.1. Marketing Strategy
23.3.11.5.2. Product Strategy
23.3.11.5.3. Channel Strategy
23.3.12. Dr.Reddy's Laboratories Inc.,
23.3.12.1. Overview
23.3.12.2. Product Portfolio
23.3.12.3. Profitability by Market Segments (Product/Channel/Region)
23.3.12.4. Sales Footprint
23.3.12.5. Strategy Overview
23.3.12.5.1. Marketing Strategy
23.3.12.5.2. Product Strategy
23.3.12.5.3. Channel Strategy
23.3.13. Cumberland Pharmaceuticals Inc.
23.3.13.1. Overview
23.3.13.2. Product Portfolio
23.3.13.3. Profitability by Market Segments (Product/Channel/Region)
23.3.13.4. Sales Footprint
23.3.13.5. Strategy Overview
23.3.13.5.1. Marketing Strategy
23.3.13.5.2. Product Strategy
23.3.13.5.3. Channel Strategy
23.3.14. Durata Therapeutics Inc.
23.3.14.1. Overview
23.3.14.2. Product Portfolio
23.3.14.3. Profitability by Market Segments (Product/Channel/Region)
23.3.14.4. Sales Footprint
23.3.14.5. Strategy Overview
23.3.14.5.1. Marketing Strategy
23.3.14.5.2. Product Strategy
23.3.14.5.3. Channel Strategy
23.3.15. Melinta Therapeutics, Inc.
23.3.15.1. Overview
23.3.15.2. Product Portfolio
23.3.15.3. Profitability by Market Segments (Product/Channel/Region)
23.3.15.4. Sales Footprint
23.3.15.5. Strategy Overview
23.3.15.5.1. Marketing Strategy
23.3.15.5.2. Product Strategy
23.3.15.5.3. Channel Strategy
23.3.16. Debiopharm International S.A.
23.3.16.1. Overview
23.3.16.2. Product Portfolio
23.3.16.3. Profitability by Market Segments (Product/Channel/Region)
23.3.16.4. Sales Footprint
23.3.16.5. Strategy Overview
23.3.16.5.1. Marketing Strategy
23.3.16.5.2. Product Strategy
23.3.16.5.3. Channel Strategy
23.3.17. Cardinal Health
23.3.17.1. Overview
23.3.17.2. Product Portfolio
23.3.17.3. Profitability by Market Segments (Product/Channel/Region)
23.3.17.4. Sales Footprint
23.3.17.5. Strategy Overview
23.3.17.5.1. Marketing Strategy
23.3.17.5.2. Product Strategy
23.3.17.5.3. Channel Strategy
23.3.18. Amazon Inc.
23.3.18.1. Overview
23.3.18.2. Product Portfolio
23.3.18.3. Profitability by Market Segments (Product/Channel/Region)
23.3.18.4. Sales Footprint
23.3.18.5. Strategy Overview
23.3.18.5.1. Marketing Strategy
23.3.18.5.2. Product Strategy
23.3.18.5.3. Channel Strategy
23.3.19. Herbal Intervention, LLC
23.3.19.1. Overview
23.3.19.2. Product Portfolio
23.3.19.3. Profitability by Market Segments (Product/Channel/Region)
23.3.19.4. Sales Footprint
23.3.19.5. Strategy Overview
23.3.19.5.1. Marketing Strategy
23.3.19.5.2. Product Strategy
23.3.19.5.3. Channel Strategy
23.3.20. 3M ESPE Dental Products
23.3.20.1. Overview
23.3.20.2. Product Portfolio
23.3.20.3. Profitability by Market Segments (Product/Channel/Region)
23.3.20.4. Sales Footprint
23.3.20.5. Strategy Overview
23.3.20.5.1. Marketing Strategy
23.3.20.5.2. Product Strategy
23.3.20.5.3. Channel Strategy
23.3.21. Patterson Dental Supply Inc.
23.3.21.1. Overview
23.3.21.2. Product Portfolio
23.3.21.3. Profitability by Market Segments (Product/Channel/Region)
23.3.21.4. Sales Footprint
23.3.21.5. Strategy Overview
23.3.21.5.1. Marketing Strategy
23.3.21.5.2. Product Strategy
23.3.21.5.3. Channel Strategy
23.3.22. The Kroger Company
23.3.22.1. Overview
23.3.22.2. Product Portfolio
23.3.22.3. Profitability by Market Segments (Product/Channel/Region)
23.3.22.4. Sales Footprint
23.3.22.5. Strategy Overview
23.3.22.5.1. Marketing Strategy
23.3.22.5.2. Product Strategy
23.3.22.5.3. Channel Strategy
23.3.23. Crown Laboratories, Inc.
23.3.23.1. Overview
23.3.23.2. Product Portfolio
23.3.23.3. Profitability by Market Segments (Product/Channel/Region)
23.3.23.4. Sales Footprint
23.3.23.5. Strategy Overview
23.3.23.5.1. Marketing Strategy
23.3.23.5.2. Product Strategy
23.3.23.5.3. Channel Strategy
23.3.24. Atlantic Biologicals Corp.
23.3.24.1. Overview
23.3.24.2. Product Portfolio
23.3.24.3. Profitability by Market Segments (Product/Channel/Region)
23.3.24.4. Sales Footprint
23.3.24.5. Strategy Overview
23.3.24.5.1. Marketing Strategy
23.3.24.5.2. Product Strategy
23.3.24.5.3. Channel Strategy
23.3.25. Bio-Germ Protection LLC
23.3.25.1. Overview
23.3.25.2. Product Portfolio
23.3.25.3. Profitability by Market Segments (Product/Channel/Region)
23.3.25.4. Sales Footprint
23.3.25.5. Strategy Overview
23.3.25.5.1. Marketing Strategy
23.3.25.5.2. Product Strategy
23.3.25.5.3. Channel Strategy
23.3.26. Apollo Health and Beauty Care
23.3.26.1. Overview
23.3.26.2. Product Portfolio
23.3.26.3. Profitability by Market Segments (Product/Channel/Region)
23.3.26.4. Sales Footprint
23.3.26.5. Strategy Overview
23.3.26.5.1. Marketing Strategy
23.3.26.5.2. Product Strategy
23.3.26.5.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
Explore Healthcare Insights
View Reports
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market
